First Quarter 2022 Highlights Product revenue of $371.0 million, up 54% year over year Total revenue of $954.8 million, up 34% year over year Bookings of $1.28 billion, up 50% year over year1 Billings of $1.16 billion, up 36% year over year2 Deferred revenue of $3.66 billion, up 33% year over year GAAP operating margin […]
–5th approved indication by NMPA significantly expands eligible patient population SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the China National Medical Products Administration (NMPA) has […]
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment. The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals. Paris, France, 16 March 2022 – Jeito Capital (“Jeito”), a leading independent […]